emapticap pegol

Emapticap pegol (NOX-E36) is an injectable PEGylated L-stereoisomer RNA aptamer, also known as a Spiegelmer, that specifically binds and neutralizes the human chemokine CCL2 (C-C motif ligand 2, also called monocyte chemoattractant protein-1 or MCP-1), as well as three highly related chemokines. By inhibiting CCL2, NOX-E36 blocks the recruitment and differentiation of inflammatory cells such as monocytes/macrophages mediated by MCP-1. This mechanism targets key pathways involved in inflammation and fibrosis. Emapticap pegol has completed Phase 1 and Phase 2 clinical studies in over 100 subjects for diabetic nephropathy, demonstrating safety, tolerability, and dose-dependent targeting of macrophages. More recently, it is being developed for ophthalmology indications such as glaucoma filtration surgery to prevent post-surgical fibrosis with a favorable safety profile compared to current standards like mitomycin C. The drug was originally developed by TME Pharma (formerly Noxxon Pharma) with ongoing collaborations including the Singapore Eye Research Institute[1][3][5][6].

Other names

emapticap pegol